摘要
目的观察联合、单用拉米夫定或干扰素治疗慢性乙型肝炎的疗效。方法选择我院2010年1月～2011年12月住院的HBeAg阳性慢性乙型肝炎患者150例,随机分为3组,每组50例。分别采用联合、单用拉米夫定或干扰素治疗。结果单用拉米夫定、干扰素或两药联合治疗对降低HBV DNA均有效,但三种疗法均各自存在局限性。组间比较发现,治疗后与随访结束后,3组间的HBV DNA阴转人数和下降人数差异均无统计学意义。三组患者在治疗后及随访结束时,HBeAg阴转人数、HBeAg血清转换人数组间组内变化比较差异均无统计学意义。结论目前临床上仍缺乏非常有效的治疗慢性乙型肝炎的疗法,三种疗法治疗效果相当,但联合疗法可以降低病毒变异和耐药的发生。
Objective To observate effect of Lamivudine or interferon treatment of patients with chronic hepatitis. Methods January 2010 to December 2011,150 patients with HBeAg positive chronic hepatitis B were randomly divided into 3 groups. Used Lamivudine or interferon therapy. Results With lamivudine, interferon or a combination of the two sequential therapy on reducing HBV DNA was effective, but the three therapies were respective limitations. Comparisons between groups were found, after the treatment and follow-up after the end, between the three groups in HBV DNA overcast num- ber decreased number and there were no significant differences. Three groups of patients after treatment and at the end of the follow-up, HBeAg overcast number, HBeAg seroconversion among number group comparison showed no significant dif- ferences in changes. Conclusion At present on clinical still lack effective treatment of chronic hepatitis B therapy, three kinds of therapy is very effective, but the sequential therapy can reduce the occurrence of virus mutation and drug resistance.
出处
《中国现代医生》
2012年第15期57-59,共3页
China Modern Doctor
